Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06706921 · ClinicalTrials.gov registry record · Phase 4
18F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer
A Phase 4 study of Neoplasms and Prostatic Neoplasms, sponsored by VA Greater Los Angeles Healthcare System.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT06706921 is a Phase 4 study of Neoplasms and Prostatic Neoplasms that is actively recruiting participants, run by VA Greater Los Angeles Healthcare System. The registered enrollment target is 15 participants, below the 1,621-participant average among 158 other Neoplasms trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06706921, a Phase 4 study of Neoplasms and Prostatic Neoplasms, is actively recruiting participants, sponsored by VA Greater Los Angeles Healthcare System.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
This a single-center, prospective, exploratory study. Patients with metastatic castration-resistant prostate cancer (mCRPC) scheduled to undergo Lutetium labelled prostate-specific membrane antigen radioligand therapy (LuPSMA RLT) at the West Los Angeles VA (WLA-VA) will be imaged with a baseline F-18 fluorodeoxyglucose positron emission tomography/computed tomography 18F-FDG PET/CT and a 18F-DCFPyL PET/CT (18F-DCFPyL (2-(3-{1-carboxy-5-\[(6-18F-fluoro-pyridine-3-carbonyl)-amino\]-pentyl}-ureido)-pentanedioic acid)positron emission tomography/computed tomography , as per standard of care in our institution. All patients further undergo eventual follow-up prostate-specific membrane antigen positron emission tomography (PSMA PET) after the 2nd, 4th, and 6th LuPSMA RLT cycle. In this prospective study, an18F-Fluciclovine positron emission tomography/computed tomography ( Axumin PET/CT )will be additionally obtained at baseline (pre-LuPSMA RLT), and after the 2nd, 4th, 6th LuPSMA RLT cycles. Axumin PET/CT will be acquired within 7 days from the PSMA PET. This study is open to Veterans only.
Conditions Studied
Interventions
- DRUG 18F-Fluciclovine PET/CT Scan
Study Locations (1)
California
- VA Greater Los Angeles Healthcare System - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2024-12-15 |
| Est. Completion | 2027-11-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06706921
The ClinicalTrials.gov registry entry for NCT06706921 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,621-participant average among 158 other Neoplasms trials with a reported enrollment target (99% lower). The listed sponsor is VA Greater Los Angeles Healthcare System, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which 18F-Fluciclovine PET/CT Scan is the first listed.
NCT06706921 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT06706921 about?
NCT06706921 is a clinical study titled "18F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer". This a single-center, prospective, exploratory study. Patients with metastatic castration-resistant prostate cancer (mCRPC) scheduled to undergo Lutetium labelled prostate-specific membrane antigen radioligand therapy (LuPSMA RLT) at the West Los Angeles VA (WLA-VA) will be imaged with a baseline F-...
What is the current status of trial NCT06706921?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 15 participants. The study started on 2024-12-15. Estimated completion is 2027-11-01.
What conditions does trial NCT06706921 study?
This clinical trial studies the following conditions: Neoplasms, Prostatic Neoplasms, Metastatic Prostate Cancer, Neoplasms by Site, Urogenital Neoplasms.
What interventions are being tested in trial NCT06706921?
The interventions under investigation include: 18F-Fluciclovine PET/CT Scan (DRUG).
Who is sponsoring clinical trial NCT06706921?
This trial is sponsored by VA Greater Los Angeles Healthcare System, which has 23 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06706921 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Improving Complete Endoscopic Mucosal Resection (EMR) of Colorectal Neoplasia
COMPLETED · Phase 4
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)
RECRUITING · Phase 1
-
Real World Registry for Use of the Ion Endoluminal System
RECRUITING
-
A Study of GSK5764227 in Participants With. Advanced Solid Tumors (EMBOLD PanTumor-101)
RECRUITING · Phase 1
-
Endometrial Cell Collection With the PadKit
RECRUITING · NA
-
Adoptive Cell Therapy Long-term Follow-up (LTFU) Study
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.